Washington, DC - Our commitment never wavers. On this Memorial Day weekend, we highlight our Service to the Armed Forces and how the Red Cross helps members of the military, veterans and their families prepare for, cope with, and respond to the challenges of military service.

Washington, DC - The United States supports the desire of the Venezuelan people to recover their democracy and bring the illegitimate Maduro regime to an end. Previous efforts to negotiate an end to the regime and free elections have failed because the regime has used them to divide the opposition and gain time.

Washington, DC - On May 23, the United States of America hosted the 16th U.S.-EU Information Society Dialogue (ISD) in Washington, D.C. Robert Strayer, Deputy Assistant Secretary for Cyber and International Communications and Information Policy, U.S. Department of State, and Roberto Viola, Director General for Communications Networks, Content and Technology (DG CONNECT), European Commission, co-chaired the dialogue.

Washington, DC - Today, the United States of America and the Kingdom of the Netherlands are pleased to announce Advisor to the President Ivanka Trump and business leader Mastercard CEO Ajay Banga will lead the closing session at the Global Entrepreneurship Summit (GES) on Wednesday, June 5, 2019, in The Hague, The Netherlands.  Manisha Singh, Assistant Secretary for Economic and Business Affairs, will moderate the session.  Co-hosted by U.S. Secretary of State Michael R. Pompeo and The Netherlands Prime Minister Mark Rutte, GES 2019 is the ninth gathering of entrepreneurs, business leaders, supporters, and government officials.

Washington, DC - Friday, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

Washington, DC - The U.S. Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality.